|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 134.48 EUR | +0.02% |
|
-0.04% | -3.86% |
| Mar. 12 | Roche ups the ante in obesity |  |
| Mar. 12 | Chemical industry sees no end to the crisis - pharma is growing | DP |
| Capitalization | 58.46B 63.59B 56.26B 49.23B 91.54B 5,529B 101B 645B 244B 2,332B 238B 234B 9,431B | P/E ratio 2025 * |
17.6x | P/E ratio 2026 * | 15.9x |
|---|---|---|---|---|---|
| Enterprise value | 63.98B 69.6B 61.58B 53.89B 100B 6,052B 110B 706B 268B 2,553B 261B 256B 10,322B | EV / Sales 2025 * |
2.9x | EV / Sales 2026 * | 2.68x |
| Free-Float |
29.72% | Yield 2025 * |
1.81% | Yield 2026 * | 1.94% |
More valuation ratios
* Estimated data
More news
Last Transcript: Merck KGaA
| MERCK KGAA : UBS reaffirms its Buy rating | Mar. 12 | ZD |
| MERCK KGAA : Goldman Sachs remains its Buy rating | Mar. 11 | ZD |
| MERCK KGAA : UBS lowers price target | Mar. 07 | CF |
| MERCK KGAA : UBS reaffirms its Buy rating | Mar. 07 | ZD |
| MERCK KGAA : Deutsche Bank reiterates its Buy rating | Mar. 07 | ZD |
More press releases
More news
| 1 day | -0.20% | ||
| 1 week | -0.77% | ||
| Current month | -1.18% | ||
| 1 month | -1.18% | ||
| 3 months | -4.44% | ||
| 6 months | -19.03% | ||
| Current year | -3.90% |
1 week
131.6
134.45
1 month
131.6
134.45
Current year
131.6
134.45
1 year
131.6
134.45
3 years
131.6
134.45
5 years
76.22
134.45
10 years
70.68
134.45
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 2021-04-30 | |
| Director of Finance/CFO | 54 | 2023-06-30 | |
Danny Bar-Zohar
CTO | Chief Tech/Sci/R&D Officer | - | 2022-02-28 |
| Director | Title | Age | Since |
|---|---|---|---|
Christian Raabe
BRD | Director/Board Member | - | 2019-04-25 |
Jürgen Glaser
BRD | Director/Board Member | 62 | 2012-04-30 |
| Director/Board Member | 76 | 2014-05-08 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 2.01% | 0 M€ | +50.45% | - | |
| 2.01% | 1 M€ | 0.00% | - | |
| 1.8% | 962 M€ | -.--% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.04% | -0.77% | -14.28% | -28.20% | 63.59B | ||
| +0.05% | -3.07% | -24.46% | -25.61% | 7.69B | ||
| +1.98% | +2.12% | +52.40% | +72.64% | 7.67B | ||
| +3.65% | +4.96% | +68.65% | +133.21% | 6.43B | ||
| +1.43% | -0.28% | +13.53% | +17.01% | 5.75B | ||
| +1.72% | -6.56% | +5.74% | -3.62% | 2.91B | ||
| +1.67% | +3.12% | +28.67% | +24.78% | 2.15B | ||
| +0.29% | -2.53% | -5.22% | +0.58% | 1.74B | ||
| +2.42% | +0.56% | -50.93% | +52.54% | 1.71B | ||
| -.--% | -.--% | - | - | 1.64B | ||
| Average | +1.30% | +0.13% | +8.23% | +27.04% | 10.13B | |
| Weighted average by Cap. | +0.47% | -0.31% | -1.94% | -3.46% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 22.04B 23.98B 21.21B 18.56B 34.51B 2,085B 37.96B 243B 92.17B 879B 89.88B 88.06B 3,556B | 22.97B 24.99B 22.11B 19.34B 35.96B 2,172B 39.56B 253B 96.05B 916B 93.66B 91.76B 3,705B |
| Net income | 3.32B 3.61B 3.19B 2.79B 5.19B 314B 5.71B 36.6B 13.87B 132B 13.53B 13.25B 535B | 3.64B 3.96B 3.5B 3.06B 5.7B 344B 6.27B 40.14B 15.21B 145B 14.84B 14.54B 587B |
| Net Debt | 5.52B 6.01B 5.32B 4.65B 8.65B 523B 9.52B 60.95B 23.1B 220B 22.53B 22.07B 891B | 3.13B 3.4B 3.01B 2.63B 4.9B 296B 5.39B 34.5B 13.08B 125B 12.75B 12.49B 504B |
More financial data
* Estimated data
Employees
59,020
Sector
Pharmaceuticals
Calendar
Apr. 24
- Annual General Meeting
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-03-17 | 134.50 € | +0.04% | 52,114 |
| 25-03-14 | 134.45 € | +0.04% | 307,647 |
| 25-03-13 | 134.40 € | +0.11% | 235,090 |
| 25-03-12 | 134.25 € | +0.04% | 354,209 |
| 25-03-11 | 134.20 € | -0.26% | 455,638 |
Delayed Quote Xetra, March 14, 2025 at 12:35 pm EDT
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
134.45EUR
Average target price
177.56EUR
Spread / Average Target
+32.07%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRK Stock